FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in Multiple Myeloma
Two CAR T-cell therapies for multiple myeloma won favorable recommendations for earlier use in the disease during a day-long meeting of the FDA Oncologic Drugs Advisory Committee (ODAC). By an 11-0 vote, ODAC recommended that FDA approve ciltacabtagene autoleucel (cilta-cel, Carvykti) for use as second-line therapy in certain patients with myeloma. Later in the day, […]
Novel CAR-T for Glioblastoma Induced ‘Dramatic’ Responses in Early Trial
A new approach to chimeric antigen receptor (CAR) T-cell therapy showed promise in treating recurrent glioblastoma, according to a small phase I study. In the first-in-human trial, three patients with recurrent glioblastoma who were treated with CARv3-TEAM-E T cells experienced “dramatic and rapid” tumor regression within days of receiving a single intraventricular infusion, reported Marcela […]
CAR-T Investigation: FDA Leaders Detail Decision on Cancer Risk Warning
The FDA has identified more cases of secondary T-cell malignancies following treatment with chimeric antigen receptor (CAR) T-cell therapies, cases that led the agency to demand new boxed warnings on approved agents in the class. With about 27,000 doses of the six B-cell maturation antigen (BCMA)- or CD19-directed CAR-T products having been administered in the […]
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission
SAN DIEGO — Autologous stem-cell transplantation (ASCT) led to improved outcomes as compared with CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, a retrospective analysis showed. Patients who underwent ASCT had fewer relapses at 2 years (27.8% vs 48.0%) and better progression-free survival (PFS, 66.2% vs 47.8%), and overall […]
‘We’re Not There Yet’: CAR T-Cell Therapy for Renal Cell Carcinoma
NASHVILLE, Tenn. — Chimeric antigen receptor (CAR) T-cell therapy has the potential to become standard-of-care therapy for renal cell carcinoma (RCC) that does not respond to current therapies, an RCC specialist said here. CAR T-cell therapy is not yet ready for clinical practice, but enrolling patients in the growing number of clinical trials can help […]
Tebentafusp’s OS Benefit in Uveal Melanoma Holds Up at 3 Years
MADRID — The significant survival benefit with the bispecific T-cell receptor therapy tebentafusp (Kimmtrak) held up at 3 years for selected patients with previously untreated metastatic uveal melanoma, updated results of a phase III trial demonstrated. In HLA-A*02:01-positive patients, landmark analyses showed improved overall survival (OS) at 1, 2, and 3 years with tebentafusp versus […]
Second-Line Axi-Cel Bests Standard in Relapsed/Refractory Large B-Cell Lymphoma
CHICAGO — Patients treated with the chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) in the second line for early relapsed or refractory large B-cell lymphoma had significantly longer overall survival (OS) than those treated with standard care, according to an analysis of the ZUMA-7 trial. At a median follow-up of 47.2 months […]
CAR T-Cell Therapy Shows Promise in Advanced Kidney Cancer
ORLANDO — An off-the-shelf, allogeneic chimeric antigen receptor (CAR) T-cell therapy targeting CD70 demonstrated antitumor activity in patients with advanced clear cell renal cell carcinoma (RCC), according to results from the phase I TRAVERSE trial. Three of 18 efficacy-evaluable patients (17%) responded to treatment with ALLO-316, and the disease control rate (DCR) reached 89%, reported […]
T-Cell Receptor Gene Therapy Shows Promise in Pancreatic Cancer
A novel T-cell receptor (TCR) gene therapy may be effective in treating patients with pancreatic cancer and other cancers that express the KRAS G12D mutation, researchers have found. Their case study — published in the New England Journal of Medicine (NEJM) — showed that a heavily pretreated patient with pancreatic ductal adenocarcinoma achieved a deep […]
T-cell responses may help predict protection against SARS-CoV-2 infection in individuals with and without cancer: Results may inform future COVID-19 vaccine development
T-cell responses directed against the receptor-binding domain of the SARS-CoV-2 spike protein were associated with protection from SARS-CoV-2 infection in vaccinated individuals with or without cancer, with lower T-cell responses observed in patients with blood cancers, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research. […]